Get started
Work

Building a Third-Party VST Bank From Scratch—the Cincinnati Experience

Year: 2018
Type: article
Abstract: Background: Viral infections remain a challenge to treat post HCT in children, and significantly contribute to morbidity and mortality. Virus specific T cells (VSTs) have shown tremendous clinical efficacy in treating viral infections post-HCT, with minimal toxicity and long-term efficacy. We have used donor-derived VSTs in individual patients, however not all donors are agreeable to the process, and numerous patients may benefit from VSTs who do not have an identified donor/have other disease indications.
DOI: 10.1016/j.bbmt.2017.12.673
Authors: Adam S. Nelson, Daria Heyenbruch, Angela Damen, Nan Gong, Katie Maurer, Xiang Zhu, Jamie Wilhelm, Danielle Fohl, Christine Sper, Angie Bonavita, Stella M. Davies, Carolyn Lutzko, Catherine M. Bollard, Patrick J. Hanley, Tom Leemhuis, Michael S. Grimley
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2792872503
FWCI:
Cites:
Cited by:
Related to: 10